Publications by authors named "Cyrielle Giletta"
Article Synopsis
- The study investigates the effectiveness of adalimumab (ADA) in treating intra-abdominal abscesses in patients with Crohn's disease, specifically those who avoided surgery with prior successful abscess resolution.
- Conducted over two years with 117 eligible patients, the study found that 74% of participants achieved ADA success at 24 weeks, and 72.9% maintained success without relapse or the need for surgery at 104 weeks.
- Key factors linked to ADA failure included previous abscess drainage, longer disease duration, and inflammatory changes in mesenteric fat, highlighting the importance of proper abscess management before starting ADA treatment.
Background: Phase III trials have demonstrated the efficacy of risankizumab in moderate-to-severe Crohn's disease (CD), but no real-world data are currently available. We aimed to assess the short-term effectiveness and safety of risankizumab in patients with CD.
Methods: From May 2021 to May 2022, all patients with refractory luminal CD treated with risankizumab in 22 French GETAID centres were retrospectively included.